An Open-Label Phase 2a Study Investigating the Efficacy and Safety of a Cathepsin S Inhibitor in Patients with Moderate-to-severe Psoriasis.
Journal of the American Academy of Dermatology（2021）
Key words
autoimmune,cathepsin S,inflamma-tion,inhibitor,open-label,PASI75,psoriasis,phase 2 trial
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined